225 related articles for article (PubMed ID: 28976766)
1. Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.
Li Y; Han Z; Roelle S; DeSanto A; Sabatelle R; Schur R; Lu ZR
Mol Pharm; 2017 Nov; 14(11):3906-3915. PubMed ID: 28976766
[TBL] [Abstract][Full Text] [Related]
2. Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer.
Lu ZR; Laney V; Li Y
Acc Chem Res; 2022 Oct; 55(19):2833-2847. PubMed ID: 36121350
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.
Han Z; Cheng H; Parvani JG; Zhou Z; Lu ZR
Magn Reson Med; 2018 Jun; 79(6):3135-3143. PubMed ID: 29082597
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Assessment of the Effectiveness of Magnetic Resonance Molecular Imaging of Extradomain-B Fibronectin for Detection and Characterization of Oral Cancer.
Hall RC; Ayat NR; Qiao PL; Vaidya AM; Ma D; Aminoshariae A; Stojanov I; Lu ZR
Mol Imaging Biol; 2020 Dec; 22(6):1532-1542. PubMed ID: 32789648
[TBL] [Abstract][Full Text] [Related]
5. Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.
Han Z; Li Y; Roelle S; Zhou Z; Liu Y; Sabatelle R; DeSanto A; Yu X; Zhu H; Magi-Galluzzi C; Lu ZR
Bioconjug Chem; 2017 Apr; 28(4):1031-1040. PubMed ID: 28201871
[TBL] [Abstract][Full Text] [Related]
6. EDB Fibronectin Specific Peptide for Prostate Cancer Targeting.
Han Z; Zhou Z; Shi X; Wang J; Wu X; Sun D; Chen Y; Zhu H; Magi-Galluzzi C; Lu ZR
Bioconjug Chem; 2015 May; 26(5):830-8. PubMed ID: 25848940
[TBL] [Abstract][Full Text] [Related]
7. MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.
Tan M; Burden-Gulley SM; Li W; Wu X; Lindner D; Brady-Kalnay SM; Gulani V; Lu ZR
Pharm Res; 2012 Apr; 29(4):953-60. PubMed ID: 22139536
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin.
Vaidya A; Ayat N; Buford M; Wang H; Shankardass A; Zhao Y; Gilmore H; Wang Z; Lu ZR
Theranostics; 2020; 10(24):11127-11143. PubMed ID: 33042274
[TBL] [Abstract][Full Text] [Related]
9. An efficient MRI agent targeting extracellular markers in prostate adenocarcinoma.
Pagoto A; Tripepi M; Stefania R; Lanzardo S; Livio Longo D; Garello F; Porpiglia F; Manfredi M; Aime S; Terreno E
Magn Reson Med; 2019 Mar; 81(3):1935-1946. PubMed ID: 30257047
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts.
Qiao P; Ayat NR; Vaidya A; Gao S; Sun W; Chou S; Han Z; Gilmore H; Winter JM; Lu ZR
Front Oncol; 2020; 10():586727. PubMed ID: 33194740
[TBL] [Abstract][Full Text] [Related]
11. Preparation and Evaluation of ZD2 Peptide
Han Z; Sergeeva O; Roelle S; Cheng H; Gao S; Li Y; Lee Z; Lu ZR
ACS Omega; 2019 Jan; 4(1):1185-1190. PubMed ID: 30729224
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance molecular imaging of extradomain B fibronectin enables detection of pancreatic ductal adenocarcinoma metastasis.
Qiao PL; Gargesha M; Liu Y; Laney VEA; Hall RC; Vaidya AM; Gilmore H; Gawelek K; Scott BB; Roy D; Wilson DL; Lu ZR
Magn Reson Imaging; 2022 Feb; 86():37-45. PubMed ID: 34801672
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer.
Wu X; Burden-Gulley SM; Yu GP; Tan M; Lindner D; Brady-Kalnay SM; Lu ZR
Bioconjug Chem; 2012 Aug; 23(8):1548-56. PubMed ID: 22812444
[TBL] [Abstract][Full Text] [Related]
14. Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging.
Tan M; Wu X; Jeong EK; Chen Q; Lu ZR
Biomacromolecules; 2010 Mar; 11(3):754-61. PubMed ID: 20131758
[TBL] [Abstract][Full Text] [Related]
15. EDB-FN Targeted Peptide-Drug Conjugates for Use against Prostate Cancer.
Park SE; Shamloo K; Kristedja TA; Darwish S; Bisoffi M; Parang K; Tiwari RK
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31277465
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of a targeted nanoglobular dual-modal imaging agent for MR imaging and image-guided surgery of prostate cancer.
Tan M; Ye Z; Lindner D; Brady-Kalnay SM; Lu ZR
Pharm Res; 2014 Jun; 31(6):1469-76. PubMed ID: 23471641
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218.
Li Y; Gao S; Jiang H; Ayat N; Laney V; Nicolescu C; Sun W; Tweedle MF; Lu ZR
Invest Radiol; 2022 Oct; 57(10):639-654. PubMed ID: 35703463
[TBL] [Abstract][Full Text] [Related]
18. Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI.
Zhou Z; Wu X; Kresak A; Griswold M; Lu ZR
Biomaterials; 2013 Oct; 34(31):7683-93. PubMed ID: 23863450
[TBL] [Abstract][Full Text] [Related]
19. Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent.
Zhang W; Liang X; Zhang X; Tong W; Shi G; Guo H; Jin Z; Tian J; Du Y; Xue H
Eur J Nucl Med Mol Imaging; 2024 Feb; ():. PubMed ID: 38372766
[TBL] [Abstract][Full Text] [Related]
20. MR molecular imaging of prostate cancer with a small molecular CLT1 peptide targeted contrast agent.
Wu X; Lindner D; Yu GP; Brady-Kalnay S; Lu ZR
J Vis Exp; 2013 Sep; (79):. PubMed ID: 24056726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
